Home › Compare › NSVLF vs ABBV
NSVLF yields 444.44% · ABBV yields 3.06%● Live data
📍 NSVLF pulled ahead of the other in Year 1
Combined, NSVLF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NSVLF + ABBV for your $10,000?
AuQ Gold Mining Inc., an exploration stage company, engages in the exploration of resource properties in Canada. It primarily explores for gold deposits. The company holds 100% interest in the Kirkland Creek gold property comprising 144 claims that covers an area of total 7,300 acres approximately located in the Ashihik Lake region to the northwest of Whitehorse, Yukon; and the Partridge gold project that comprises 95 mineral claims covering 52.68 square kilometers situated in Abitibi, Quebec. It also has an option to acquire a 100% interest in Sainte Sabine property located in the Beauce region of Quebec; and the Eliza Gold Project consisting of 8 mineral claims situated in Quebec. The company was formerly known as Royal Gold Mining Inc. and changed its name to AuQ Gold Mining Inc. in October 2020. AuQ Gold Mining Inc. was incorporated in 2005 and is based in Vancouver, Canada.
Full NSVLF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.